This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Initial Findings of Cross-Industry CBD Study Show No Evidence of Liver Toxicity
Company met with FDA earlier this month to review results.
HempFusion Wellness Inc. has announced that Validcare, the organization coordinating the execution of an observational liver and human toxicology study, has released its initial findings from the industry sponsored, decentralized human safety study of hemp derived CBD products.
According to the study’s investigators, initial findings show there was no evidence of liver toxicity in the 839 participants in the clinical trials. Eleven other companies participated, including Charlotte's Web and CannaCraft.